Dermavant Is Committed to Fostering Unprecedented Change And

CORPORATE FACT SHEET Issued August 2020

Dermavant is committed to Dermavant at-a-glance fostering unprecedented change • Clinical-stage and unparalleled impact in biopharmaceutical company immuno-dermatology. • Founded September 2015 • A subsidiary of Roivant Sciences We’re doing this by thinking differently, pushing the • U.S. operations in Long Beach, boundaries of science and partnering with providers California and Raleigh-Durham, in new ways—all with one goal: transforming the North Carolina lives of millions of patients with skin diseases.

About Dermavant Management team

A Passion for Science and a Commitment to Dermatology Todd Zavodnick Chief Executive Officer Dermavant Sciences, a subsidiary of Roivant Sciences, is a clinical- stage bio-pharmaceutical company focused on developing products Philip M. Brown, MD, JD that represent new treatment categories and address some of the Chief Medical Officer greatest challenges providers and patients encounter.

The company’s robust medical dermatology pipeline includes Chris Chapman both late-stage and early-development product candidates that Chief Commercial Officer target specific unmet needs in two of the largest growing immuno- dermatology markets, psoriasis and atopic dermatitis, as well as David Rubenstein, MD, PhD other large markets, including vitiligo, primary focal hyperhidrosis, Chief Scientific Officer and acne. Christopher Van Tuyl, JD Dermavant is developing its lead product candidate, tapinarof General Counsel (DMVT-505), as a novel therapeutic aryl hydrocarbon receptor modulating agent (TAMA) topical cream for the treatment of plaque psoriasis and atopic dermatitis, which affect approximately 8 million and 26 million people in the United States, respectively.

Investor Relations Key Contact To learn more, Kara Stancell · 520-858-0027 · [email protected] visit www.Dermavant.com. Dermavant has five product candidates addressing: Psoriasis · Atopic Dermatitis · Vitiligo · Hyperhidrosis · Acne

PRODUCT CANDIDATE INDICATION STAGE OF DEVELOPMENT

Preclinical Phase 1 Phase 2 Phase 3

Tapinarof (DMVT-505) Psoriasis A topical, therapeutic AhR modulating agent (TAMA), inhibiting several proinflammatory factors Atopic Dermatitis

Vitiligo Cerdulatinib (DMVT-502) A topical dual JAK/Syk inhibitor Atopic Dermatitis

Oxybutynin/Pilocarpine (DMVT-504) Primary Focal An oral combination of an immediate-release muscarinic Hyperhidrosis antagonist with a delayed-release muscarinic agonist

DMVT-503 A novel mechanism of action for the Acne Vulgaris topical treatment of acne vulgaris

Lotamilast (DMVT-501) Atopic Dermatitis A highly selective topical PDE4 inhibitor

Excludes certain Asian territories

Key market data

Psoriasis: 8M patients in U.S.1 Atopic dermatitis: 26M patients in U.S.4 Vitiligo: 0.5% to 2% of global population5 • $12.0B sales2 • $1.8B sales2 • No FDA-approved therapies

2 2 • $19.3B by 2026 • $5.7B by 2026 Hyperhidrosis: 15.3M patients in U.S.6 • Topical treatments are ~58% • Topical treatments are • No FDA-approved systemic treatments of U.S. Rxs3 ~98% of U.S. Rxs3

References: 1. National Psoriasis Foundation.2. Evaluate Pharma. 3. IQVIA National Prescription Audit (NPA), October 2020.4. National Eczema Association.5. Bergqvist C, Ezzedine K. Vitiligo: A Review.Dermatology . 2020;236:571-592. doi: 10.1159/000506103. 6. Doolittle, J. et al. Arch Dermatol Res. 2016;308:743-749; US Census.

Main Phone Number: 919-767-3277

Company locations: Long Beach, California Office Raleigh-Durham, North Carolina Office Basel, Switzerland Office Dermavant Sciences, Inc. Dermavant Sciences, Inc. Dermavant Sciences GmbH 3780 Kilroy Airport Way, Suite 250 3300 Paramount Parkway, Suite 150 Viaduktstrasse 8 Long Beach, CA 90806 Morrisville, NC 27560 4051 Basel